Changes to the Special Access and Authorised Prescriber (AP) schemes, exclusively revealed by Cannabiz last week, have caused confusion over the potential impact on the prescribing process, it has emerged. 

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Senior industry figures have questioned whether approving access to medicinal cannabis products by category – rather than brand name – might permit pharmacists to dispense a different product to the one named on a prescription, as is commonly done for medicines where a generic version is available. 

Rhys Cohen

As well as being editor-at-large at Cannabiz, Rhys is the director of Cannabis Consulting Australia, which provides commercial consulting services to various domestic and international cannabis companies....